SBIR/STTR Research Award

Plant Bioproduction of ChIFN-gamma Immunostimulatory Cytokine for Poultry Diseases

Award identifier d16a7344d601340b269cf5302eda5a17c8f9cf9addaa631c3b1d5c06f4b22894Awarding agency Department of Agriculture

Award amount

$99,999

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Agriculture
Branch
Not reported
Recipient company
GENECOME BIOTECH LC
Proposal award date
2015-04-23
Contract end date
Not reported
UEI
FWVKWP33NJ69
Solicitation number
Not reported
Topic code
8.3

Research abstract

Poultry is a large component of livestock animals representing a multi-billion dollar industry. Chickens are raised under high density conditions and exposure to infections by opportunistic pathogens spreads rapidly and can have devastating economic impact. Cytokines such as Chicken Interferon-gamma (ChIFN-γ) have shown to have adjuvant and growth promoting activity in poultry and livestock. Their potential is very promising to be used as immunoenhancers adjuvants and as an alternative to antibiotics. The goal of this proposal SBIR Phase I is to produce chicken interferon-gamma in our rapid plant production system to use as a potent immunostimulant against poultry diseases. Current commercially available ChIFN-γ are cost-prohibited ($1,300-2,000 / 100μg of protein). The primary drawback of these current systems (yeast, E.coli) is their inability to offer production at a large scale. Our plant system offer a number of benefits over conventional culture systems. These include: 1) a low starting cost, 2) the capacity to express an active form of complex proteins that require post-translational modifications, 3) scalable manufacturing capacity, and 4) high safety, no human or mammalian pathogens.We will produce recombinant chicken interferon-gamma protein in transgenic tobacco plants. We will harvest the leaves, isolate the ChIFN-γ protein, purify, characterize and test its bioactivity. Phase I will determine the ability of plants to produce bioactive chicken IFN-γ in vitro, and will provide the yield level capacity of the avian cytokine. We expect that if found feasible, the ChIFN-γ immunomodulator agent may represent a promising low-cost research reagent for pharmaceuticals, basic research and commercial applications. The research reagent market is a $40.3 billion dollar industry expected to extend to $81 billion by 2016 (BCC Research). Our reagents will serve as valuable tools for basic and applied research in the area of poultry immunology.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Agriculture

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.